KB103 for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Condition: Dystrophic Epidermolysis Bullosa Intervention: Biological: KB103 Sponsor: Krystal Biotech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Epidermolysis Bullosa